Jersey brand

Lupin’s New Jersey branch gets thirteen sightings


The after-hours pharmaceutical major announced on Thursday that its wholly owned subsidiary Novel Laboratories based in Somerset, New Jersey (USA) had received thirteen observations from the USFDA.

The facility was subject to a USFDA inspection from March 7, 2022 through March 30, 2022.

Lupine promised to respond to those comments and said he would work closely with the agency to address their concerns. Additionally, the company said the observations will not impact the disruption of supplies or existing revenue from operations. The facility contributes less than 5% of the company’s global revenue.



The drugmaker has ensured compliance with good manufacturing practice standards at all of its facilities.

Lupine is a transnational pharmaceutical company. The company develops and markets a wide range of branded and generic formulations, biotechnology products and APIs in more than 100 markets in the United States, India, South Africa and Asia-Pacific (APAC) regions, Latin America (LATAM), Europe and Middle East. .

The company’s consolidated net profit jumped by 24.47% to Rs 545.52 crore on a 3.57% increase in total operating income to Rs 4160.93 crore in Q3 FY22 compared to Q3 FY21.

Shares of Lupine were trading up 1.36% at Rs 756.20 on BSE.

Powered by Capital Market – Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear reader,

Business Standard has always endeavored to provide up-to-date information and commentary on developments that matter to you and that have wider political and economic implications for the country and the world. Your constant encouragement and feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these challenging times stemming from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative opinions and incisive commentary on relevant topical issues.
However, we have a request.

As we battle the economic impact of the pandemic, we need your support even more so that we can continue to bring you more great content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.

Support quality journalism and subscribe to Business Standard.

digital editor